Loading
ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for HER2-expressing advanced solid tumours, including HER2-positive breast cancer; development has stopped.
ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics. A HER2-targeted antibody carrying a GSPT1-degrading payload into cancer cells. Its furthest stage is phase 1, for HER2-expressing advanced solid tumours, including HER2-positive breast cancer. ClinicalTrials.gov registers it in one study linked below. Orum discontinued clinical development of ORM-5029 (company release of 28 April 2025). The phase 1 NCT05511844 is TERMINATED ('Sponsor Decision'). Whether it works in people has not been established unless a trial below reports it.
A HER2-targeted antibody carrying a GSPT1-degrading payload into cancer cells. Connects to HER2.
1.ORM-5029 binds HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ORM-5029" OR ABSTRACT:"ORM-5029") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ORM-5029, not a curated reading list.
Shares Orum Therapeutics and the tags pipeline, discontinued.
Shares HER2, HER2-positive breast cancer and the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/